Christopher Parker

18.8k citations

60 papers · 6.6k indexed · 5 hit papers · h-index 30

Impact in

Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism

Papers in

Pulmonary and Respiratory Medicine 49
- Prostate Cancer Treatment and Research 47
- Prostate Cancer Diagnosis and Treatment 27
Radiology, Nuclear Medicine and Imaging 24
- Radiopharmaceutical Chemistry and Applications 20
- Medical Imaging Techniques and Applications 3

Co-authors: Johann S. de Bono Howard I. Scher Leon W.M.M. Terstappen Gerald V. Doyle H. Tissing Michael Craig Miller Derek Raghavan Kenneth J. Pienta
Journals: European Urology (9 papers)British Journal of Urology (6 papers)The Lancet Oncology (3 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)Journal of Clinical Oncology (3 papers)
Partner nations: United Kingdom United States Sweden

In The Last Decade

Christopher Parker

59 papers receiving 6.5k citations

Hit Papers

5 papers align trajectories log scale

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data 2020 · 185 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 The Lancet
2014 The Lancet Oncology
2012 European Urology
2008 Clinical Cancer Research
2008 Journal of Clinical Oncology

Peers

Countries citing papers authored by Christopher Parker

Since Specialization

Citations

This map shows the geographic impact of Christopher Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Parker more than expected).

Fields of papers citing papers by Christopher Parker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Parker. The network helps show where Christopher Parker may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Parker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Parker Line = papers co-authored together Christopher Parker links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial International Journal of Radiation OncologyBiologyPhysics ·René Horsleben Petersen, Adrian Cook, Matthew R. Sydes, Noel W. Clarke, William Cross, Howard Kynaston, John Logue, 田畑友子, Heather Payne, Mahesh Parmar, Wendy R. Parulekar, Raj Persad, Fred Saad, G. V. Popovich, Christopher Parker, Charles Catton	2023	8
2	The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases European Radiology ·Gunther Roelkens, Nina Tunariu, Holly Tovey, Emma Hall, Sue Chua, Gary Cook, Yong Du, Matthew Blackledge, Christopher Parker, Dow‐Mu Koh	2023	4
3	RADICALS trial statistical analysis plan Zenodo (CERN European Organization for Nuclear Research) ·Christopher Parker, Mahesh Parmar, Matthew R. Sydes, Adrian Cook	2022	1
4	Considering benefit and risk before routinely recommending SpaceOAR The Lancet Oncology ·William A. Hall, Alison Tree, David P. Dearnaley, Christopher Parker, Vinay Prasad, Mack Roach, C.A. Lawton	2020	29
5	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1\|RT Comparison” European Urology Oncology ·Adnan Ali, Alex Hoyle, Christopher Parker, Chris Brawley, Adrian Cook, Claire Amos, J. Calvert, Hassan Douis, Malcolm D. Mason, Gerhardt Attard, Mahesh Parmar, Matthew R. Sydes, Nicholas D. James, Noel W. Clarke	2020	11
6	Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer European Urology Oncology ·Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, Christopher Parker, Paul L. Nguyen, Andrew J. Stephenson, C. Carrié	2018	7
7	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial European Urology ·Christopher Parker, Steven E. Finkelstein, Jeff M. Michalski, Joe M. O’Sullivan, Øyvind S. Bruland, Nicholas J. Vogelzang, Robert E. Coleman, Sten Nilsson, Oliver Sartor, Rui Li, Monica Seger, David Bottomley	2016	51
8	Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial Clinical Genitourinary Cancer ·Nicholas J. Vogelzang, Robert E. Coleman, Jeff M. Michalski, Sten Nilsson, Joe M. O’Sullivan, Christopher Parker, Anders Widmark, Marcus Thuresson, Lei Xu, Ichikawa Hinayo, Oliver Sartor	2016	65
9	Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial European Journal of Cancer ·Christopher Parker, Lin Zhan, Paul Cislo, Jonathan Reuning‐Scherer, Nicholas J. Vogelzang, Sten Nilsson, Oliver Sartor, Joe M. O’Sullivan, Robert E. Coleman	2016	36
10	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial The Lancet Oncology ·Peter Hoskin, Oliver Sartor, Joe M. O’Sullivan, Dag Clement Johannessen, Svein Inge Helle, John Logue, David Bottomley, Sten Nilsson, Nicholas J. Vogelzang, Fang Fang, Mona Wahba, Anne-Kirsti Aksnes, Christopher Parker Hit paper breakdown →	2014	290
11	Novel Tools to Improve Patient Selection and Monitoring on Active Surveillance for Low-risk Prostate Cancer: A Systematic Review European Urology ·Roderick C.N. van den Bergh, Hashim U. Ahmed, Chris H. Bangma, Matthew R. Cooperberg, Arnauld Villers, Christopher Parker	2014	92
12	Active Surveillance for Prostate Cancer: A Systematic Review of the Literature European Urology ·Marc Dall’Era, Peter C. Albertsen, C. Bangma, Peter R. Carroll, H. Ballentine Carter, Matthew R. Cooperberg, Stephen J. Freedland, Laurence Klotz, Christopher Parker, Mark S. Soloway Hit paper breakdown →	2012	443
13	Use of radionuclides in metastatic prostate cancer Current Opinion in Supportive and Palliative Care ·Salil Vengalil, Joe M. O’Sullivan, Christopher Parker	2012	13
14	The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer European Journal of Nuclear Medicine and Molecular Imaging ·Gary Cook, KuanShuo Dong, Aslam Sohaib, Valerie Lewington, Sue Chua, Robert Huddart, Christopher Parker, V Muscalli, Alan Horwich	2010	44
15	Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Johann S. de Bono, Howard I. Scher, Bruce Montgomery, Christopher Parker, Michael Craig Miller, H. Tissing, Gerald V. Doyle, Leon W.M.M. Terstappen, Kenneth J. Pienta, Derek Raghavan Hit paper breakdown →	2008	1744
16	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Journal of Clinical Oncology ·Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, J. W. Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono Hit paper breakdown →	2008	666
17	Predicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer Managed by Active Surveillance European Urology ·Nicholas van As, A. Norman, Karen Thomas, Vincent Khoo, Alan Thompson, Robert Huddart, Alan Horwich, David P. Dearnaley, Christopher Parker	2008	173
18	Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC) Molecular Cancer Therapeutics ·Gerhardt Attard, Alison Reid, Rajesh Kumar Sinha, R. Molife, Florence I. Raynaud, Mitch Dowsett, Mary Barrett, Emilda Thompson, Timothy A. Yap, S. Settatree, Vanessa Martins, Christopher Parker, David P. Dearnaley, Elizabeth Folkerd, Gloria Lee, Johann S. de Bono	2007	1
19	A Comparison of the Use of Bony Anatomy and Internal Markers for Offline Verification and an Evaluation of the Potential Benefit of Online and Offline Verification Protocols for Prostate Radiotherapy International Journal of Radiation OncologyBiologyPhysics ·H. McNair, Vibeke N. Hansen, Christopher Parker, Philip Evans, A. Norman, Elizabeth Miles, Emma Harris, Jacqueline Harris, А.И. Швец, Richard D. Keane, Vincent Khoo, Alan Thompson, David P. Dearnaley	2007	68
20	The management of PSA failure after radical radiotherapy for localized prostate cancer Radiotherapy and Oncology ·Christopher Parker, David P. Dearnaley	1998	29

About Christopher Parker

Christopher Parker is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Statistics and Probability, Oncology and Radiation, having authored 60 papers that have together received 6.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (47 papers), Prostate Cancer Diagnosis and Treatment (27 papers), Radiopharmaceutical Chemistry and Applications (20 papers), Bone health and treatments (13 papers), Bladder and Urothelial Cancer Treatments (5 papers), Advanced Radiotherapy Techniques (4 papers), Statistical Methods in Clinical Trials (4 papers) and Medical Imaging Techniques and Applications (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.8k citations), Cancer Research (1.8k citations), Oncology (2.4k citations), Radiology, Nuclear Medicine and Imaging (1.9k citations) and Endocrinology, Diabetes and Metabolism (674 citations). Christopher Parker has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Johann S. de Bono, Howard I. Scher, Leon W.M.M. Terstappen, Gerald V. Doyle, H. Tissing, Michael Craig Miller, Derek Raghavan, Kenneth J. Pienta, Bruce Montgomery and David P. Dearnaley. Their work appears in journals such as European Urology, British Journal of Urology, The Lancet Oncology, International Journal of Radiation Oncology*Biology*Physics and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact